Physician profile
Deepa Baswaraj
NPI 1033604053
$2,186.32
in general payments reported to CMS, 2019-2025
14 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $685 · 2022: $313 · 2023: $531 · 2024: $416 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $548.29 | 2021-2025 | Micra, Hawkone, In.Pact Admiral |
| Amgen INC. | $423.98 | 2021-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $344.10 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $212.99 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $207.97 | 2023-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $173.58 | 2021-2023 | Brilinta |
| Janssen Pharmaceuticals, INC | $81.60 | 2022-2024 | Xarelto |
| Janssen Scientific Affairs, LLC | $45.03 | 2022 | |
| Chiesi USA, INC. | $37.65 | 2022-2023 | Kengreal, Cleviprex |
| Alnylam Pharmaceuticals INC. | $34.33 | 2025 | Amvuttra |
| Zoll Circulation INC | $22.00 | 2022-2023 | Temperature Management System, Catheter, Temperature Management System Start-Up Kit |
| Daiichi Sankyo INC. | $21.53 | 2023 | Injectafer |
| Pfizer INC. | $18.25 | 2023 | |
| Cordis US Corp. | $15.02 | 2025 | Mynx Control Venous |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Baswaraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.